Ncardia is very pleased to welcome Dr. Jeroen de Groot as Divisional Chief Executive.
Jeroen is a highly accomplished R&D and Business executive with an extensive background leading international contract research organizations, with particular experience in innovation, drug discovery and development. He will be a member of the Executive Team, and will lead the Ncardia Leadership Team.
Jeroen was previously Chief Operation Officer Early Discovery at Charles River Laboratories, and held positions at contract research companies including Galapagos and TNO. He studied biology at Leiden university, and earned a PhD at Utrecht University Medical Center & TNO. He began his career as a bench scientist at TNO.
About his new role, Jeroen said, “I am very much looking forward to working with our team and our clients in leveraging Ncardia’s cutting-edge stem cell technologies to develop much-needed safe and efficacious therapies for patients.”
Ncardia and Cellistic CEO Gustavo Mahler added, “We’re thrilled to have Jeroen leading Ncardia’s efforts to accelerate drug development by bringing predictive and translational human biology early into the discovery pipeline. His experience as both a scientist and a team leader will help propel our partners’ efforts forward.”